L'intérêt à découvert pour Blue Bird donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Blue Bird. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Blue Bird (NASDAQ:BLBD) Stock, Rapport sur les intérêts à découvert

Blue Bird

Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.

Blue Bird Corp

<p>Deep-pocketed investors have adopted a bullish approach towards Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AVGO usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 50 extraordinary options activities for Broadcom. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 62% leaning bullish and 22% bearish. Among these notable options, 20 are puts, totaling $1,445,519, and 30 are calls, amounting to $2,569,643.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $110.0 to $280.0 for Broadcom over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Broadcom stands at 3176.3, with a total volume reaching 13,952.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Broadcom, situated within the strike price corridor from $110.0 to $280.0, throughout the last 30 days.</p>
<h3>Broadcom Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736359271_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AVGO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$82.4</td>
<td>$80.75</td>
<td>$81.55</td>
<td>$160.00</td>
<td>$405.5K</td>
<td>3.6K</td>
<td align="right">50</td>
</tr>
<tr>
<td>AVGO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$8.85</td>
<td>$8.4</td>
<td>$8.6</td>
<td>$136.00</td>
<td>$344.0K</td>
<td>158</td>
<td align="right">401</td>
</tr>
<tr>
<td>AVGO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$79.9</td>
<td>$77.55</td>
<td>$79.9</td>
<td>$150.00</td>
<td>$319.6K</td>
<td>17.3K</td>
<td align="right">73</td>
</tr>
<tr>
<td>AVGO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$12.7</td>
<td>$12.5</td>
<td>$12.55</td>
<td>$200.00</td>
<td>$313.7K</td>
<td>4.3K</td>
<td align="right">532</td>
</tr>
<tr>
<td>AVGO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$28.3</td>
<td>$27.1</td>
<td>$27.05</td>
<td>$200.00</td>
<td>$270.5K</td>
<td>17.8K</td>
<td align="right">155</td>
</tr>
</tbody>
</table>
</p>
<h3>About Broadcom</h3>
<p>Broadcom is the sixth-largest semiconductor company globally and has expanded into various software businesses, with over $30 billion in annual revenue. It sells 17 core semiconductor product lines across wireless, networking, broadband, storage, and industrial markets. It is primarily a fabless designer but holds some manufacturing in-house, like for its best-of-breed FBAR filters that sell into the Apple iPhone. In software, it sells virtualization, infrastructure, and security software to large enterprises, financial institutions, and governments.Broadcom is the product of consolidation. Its businesses are an amalgamation of former companies like legacy Broadcom and Avago Technologies in chips, as well as Brocade, CA Technologies, and Symantec in software.</p>
<p>Having examined the options trading patterns of Broadcom, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Broadcom</h3>
<ul>
<li>Currently trading with a volume of 7,796,945, the AVGO's price is down by -0.38%, now at $227.77. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 57 days.</li>
</ul>
<h3>Professional Analyst Ratings for Broadcom</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $227.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Baird persists with their Outperform rating on Broadcom, maintaining a target price of $210.<br />
&#x2A; Consistent in their evaluation, an analyst from Rosenblatt keeps a Buy rating on Broadcom with a target price of $250.<br />
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Broadcom, maintaining a target price of $233.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Broadcom, targeting a price of $220.<br />
&#x2A; An analyst from Susquehanna has decided to maintain their Positive rating on Broadcom, which currently sits at a price target of $225. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Broadcom with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

AVGO

Broadcom's Options: A Look at What the Big Money is Thinking

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>GE Vernova</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GEV, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 12 uncommon options trades for GE Vernova.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 50% bullish and 50%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $136,535, and 9 are calls, for a total amount of $360,521.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $95.0 to $430.0 for GE Vernova during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for GE Vernova's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of GE Vernova's whale trades within a strike price range from $95.0 to $430.0 in the last 30 days. </p>
<h3>GE Vernova 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736359266_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$43.4</td>
<td>$41.0</td>
<td>$41.0</td>
<td>$320.00</td>
<td>$61.5K</td>
<td align="right">251</td>
<td align="right">0</td>
</tr>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$61.3</td>
<td>$58.0</td>
<td>$59.2</td>
<td>$300.00</td>
<td>$59.2K</td>
<td align="right">441</td>
<td align="right">10</td>
</tr>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$4.2</td>
<td>$3.9</td>
<td>$4.2</td>
<td>$430.00</td>
<td>$58.8K</td>
<td align="right">214</td>
<td align="right">140</td>
</tr>
<tr>
<td>GEV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$65.5</td>
<td>$63.5</td>
<td>$65.5</td>
<td>$370.00</td>
<td>$52.4K</td>
<td align="right">8</td>
<td align="right">8</td>
</tr>
<tr>
<td>GEV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.1</td>
<td>$5.3</td>
<td>$6.1</td>
<td>$345.00</td>
<td>$46.0K</td>
<td align="right">20</td>
<td align="right">84</td>
</tr>
</tbody>
</table>
</p>
<h3>About GE Vernova</h3>
<p>GE Vernova is a global leader in the electric power industry, with products and services that generate, transfer, convert, and store electricity. The company has three business segments: power, wind, and electrification. Power includes gas, nuclear, hydroelectric, and steam technologies, providing dispatchable power. The wind segment includes wind generation technologies, inclusive of onshore and offshore wind turbines and blades. Electrification includes grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, and storage of electricity from the point of generation to point of consumption.</p>
<p>After a thorough review of the options trading surrounding GE Vernova, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>GE Vernova's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,904,214, with GEV's price down by -3.02%, positioned at $357.38.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 14 days.</li>
</ul>
<h3>What The Experts Say On GE Vernova</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $398.4.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on GE Vernova, maintaining a target price of $411.<br />
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for GE Vernova, targeting a price of $400.<br />
&#x2A; An analyst from Jefferies has decided to maintain their Buy rating on GE Vernova, which currently sits at a price target of $391.<br />
&#x2A; An analyst from Evercore ISI Group has decided to maintain their Outperform rating on GE Vernova, which currently sits at a price target of $390.<br />
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on GE Vernova with a target price of $400. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for GE Vernova with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


This Is What Whales Are Betting On GE Vernova

<p>Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $139.0, a high estimate of $157.00, and a low estimate of $103.00. Observing a downward trend, the current average is 5.44% lower than the prior average price target of $147.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736359263_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A clear picture of Science Applications Intl's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gautam Khanna</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$120.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$149.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Gavin Parsons</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$103.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Seth Seifman</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$148.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$154.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Gavin Parsons</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$134.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$147.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$157.00</td>
<td>$122.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Science Applications Intl. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Science Applications Intl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Science Applications Intl's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Science Applications Intl's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SAIC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Science Applications Intl analyst ratings.</strong></a></p>
<h2>About Science Applications Intl</h2>
<p>Science Applications International Corp provides technical, engineering, and enterprise IT services mainly to the U.S. government. Specifically, the company offers engineering, systems integration, and information technology for large government projects and a broad range of services with an emphasis on higher-end technology services. The company's end-to-end enterprise IT offerings span the entire spectrum of customers' IT infrastructure.</p>
<h3>Key Indicators: Science Applications Intl's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Science Applications Intl's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>4.27%</strong> as of 31 October, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Science Applications Intl's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>5.36%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Science Applications Intl's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>6.55%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Science Applications Intl's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>2.01%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Science Applications Intl's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.46</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

SAIC

Where Science Applications Intl Stands With Analysts

<p>Deep-pocketed investors have adopted a bearish approach towards SoundHound AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SOUN usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 52 extraordinary options activities for SoundHound AI. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 40% leaning bullish and 46% bearish. Among these notable options, 32 are puts, totaling $5,653,314, and 20 are calls, amounting to $1,938,820.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $4.0 to $25.0 for SoundHound AI over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for SoundHound AI options trades today is 3069.4 with a total volume of 70,026.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for SoundHound AI's big money trades within a strike price range of $4.0 to $25.0 over the last 30 days.</p>
<h3>SoundHound AI 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736359260_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SOUN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/10/25</td>
<td>$3.7</td>
<td>$3.55</td>
<td>$3.7</td>
<td>$20.00</td>
<td>$924.2K</td>
<td>15.2K</td>
<td>9</td>
</tr>
<tr>
<td>SOUN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$9.65</td>
<td>$9.5</td>
<td>$9.5</td>
<td>$8.00</td>
<td>$855.0K</td>
<td>1.5K</td>
<td>901</td>
</tr>
<tr>
<td>SOUN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/10/25</td>
<td>$3.4</td>
<td>$3.4</td>
<td>$3.4</td>
<td>$20.00</td>
<td>$850.0K</td>
<td>15.2K</td>
<td>4.1K</td>
</tr>
<tr>
<td>SOUN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$2.98</td>
<td>$2.97</td>
<td>$2.98</td>
<td>$16.00</td>
<td>$759.6K</td>
<td>1.9K</td>
<td>2.5K</td>
</tr>
<tr>
<td>SOUN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/10/25</td>
<td>$3.65</td>
<td>$3.5</td>
<td>$3.65</td>
<td>$20.00</td>
<td>$547.5K</td>
<td>15.2K</td>
<td>4.1K</td>
</tr>
</tbody>
</table>
</p>
<h3>About SoundHound AI</h3>
<p>SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers.</p>
<h3>Where Is SoundHound AI Standing Right Now?</h3>
<ul>
<li>With a volume of 62,102,606, the price of SOUN is down -17.22% at $14.88. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 50 days.</li>
</ul>
<h3>Expert Opinions on SoundHound AI</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $24.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from HC Wainwright &amp; Co. keeps a Buy rating on SoundHound AI with a target price of $26.<br />
&#x2A; An analyst from Wedbush persists with their Outperform rating on SoundHound AI, maintaining a target price of $22. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for SoundHound AI with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


SOUN

Smart Money Is Betting Big In SOUN Options

<p>In the preceding three months, 23 analysts have released ratings for First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">7</td>
<td align="right">15</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">6</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated First Solar and provided 12-month price targets. The average target is $270.48, accompanied by a high estimate of $367.00 and a low estimate of $209.00. Experiencing a 4.82% decline, the current average is now lower than the previous average price target of $284.18. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736359252_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The analysis of recent analyst actions sheds light on the perception of First Solar by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$209.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$267.00</td>
<td>$307.00</td>
</tr>
<tr>
<td>Dushyant Ailani</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$248.00</td>
<td>$257.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Andrew Percoco</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$367.00</td>
<td>$301.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Maheep Mandloi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$257.00</td>
<td>$274.00</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$335.00</td>
<td>$368.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$279.00</td>
<td>$311.00</td>
</tr>
<tr>
<td>Chris Dendrinos</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$245.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Sean Morgan</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$278.00</td>
<td>$281.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$286.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$252.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Andrew Percoco</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$297.00</td>
<td>$329.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$269.00</td>
<td>$321.00</td>
</tr>
<tr>
<td>Sean Milligan</td>
<td>Janney Montgomery Scott</td>
<td>Announces</td>
<td>Buy</td>
<td>$260.00</td>
<td>-</td>
</tr>
<tr>
<td>Vikram Bagri</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$254.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$280.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Andrew Percoco</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$329.00</td>
<td>$332.00</td>
</tr>
<tr>
<td>Philip Shen</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$280.00</td>
<td>$320.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to First Solar. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of First Solar compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of First Solar's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into First Solar's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FSLR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on First Solar analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind First Solar</h2>
<p>First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.</p>
<h3>First Solar: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> First Solar displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>10.81%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> First Solar's net margin excels beyond industry benchmarks, reaching <strong>35.26%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> First Solar's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>4.22%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> First Solar's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.79%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> First Solar's debt-to-equity ratio is below the industry average at <strong>0.09</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FSLR

Expert Outlook: First Solar Through The Eyes Of 23 Analysts

News

Trading Ideas

iShares Dow Jones US Financial Sector Index Fund

CNBC Halftime Report Final Trades: Apollo Global Management, UnitedHealth Group, iShares U.S. Financial ETF, Boston Scientific

<p>Pseudonymous cryptocurrency analyst <strong>Ali Martinez </strong>has cautioned that <strong>Bitcoin </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is vulnerable to a steep decline, citing a lack of substantial support <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42874069/bitcoin-could-drop-as-low-as-75000-if-it-fills-this-liquidity-gap-expert-warns">below the $92,000 mark</a>.</p>
<p><strong>What Happened: </strong>Ali&#8217;s analysis, shared in a <a href="https://x.com/ali_charts/status/1877007033544724711">series</a> of tweets on Wednesday, indicates that a failure to hold this level could lead to a rapid price correction down to the $74,000−$78,000.</p>
<p>Bitcoin is trading at $93,950, down 3.5% over the last 24 hours. </p>
<p>Other major altcoins like <strong>Solana </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), <strong>Dogecoin </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and <strong>Cardano </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>) are trading down 7.5% 8.5% and 11%, respectively.</p>
<p>This warning comes after Bitcoin broke below a key demand zone between $95,400 and $98,400, an area where 1.77 million addresses acquired more than 1.53 million BTC.</p>
<p>Ali pointed out that Bitcoin breached a head-and-shoulders pattern yesterday and invalidated the bearish setup.</p>
<p>A head-and-shoulders pattern is a bearish chart formation signaling a potential trend reversal, often predicting a decline in price.</p>
<p>However, he noted, that today&#8217;s price action has reversed these gains, pulling BTC back below the right shoulder and "reigniting bearish concerns".</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42878368/xrp-etf-very-soon-likely-next-after-bitcoin-and-ethereum-ripple-president-says">XRP ETF &#8216;Very Soon,&#8217; Likely Next After Bitcoin And Ethereum, Ripple President Says</a></strong></p>
<p>Ali highlighted that the break below this key demand zone is concerning because, "These holders could now be forced to sell some BTC to cut potential losses."</p>
<p>He also previously warned that a dip below $92,730 would lead to "free fall territory" for Bitcoin.</p>
<p>According to Ali, if Bitcoin falls below $92,000 "a steep drop, with little support until $74,000" could be on the cards. </p>
<p>While technical indicators such as TD Sequential suggest a potential rebound in the short-term, and the trader also mentions that, "traders on Binance are leaning bullish on Bitcoin", Ali also indicated that the wider market conditions suggest a need for caution.</p>
<p>The TD Sequential is a technical analysis indicator that identifies potential trend exhaustion and reversal points in price charts.</p>
<p><strong>What&#8217;s Next: </strong>Ali suggested that a short-term move to $98,600 is possible.</p>
<p>However he also noted there is a $35 million liquidation zone around $98,600 and that "market makers may try to grab!" </p>
<p>Despite this, and for the bearish outlook to be invalidated, Ali stressed that Bitcoin "must reclaim $100,000 to invalidate the bearish outlook and set its sights on new all-time highs".</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42878139/peter-schiff-doesnt-hate-bitcoin-but-warns-millions-will-lose-more-than-they-can-afford-in-speculative-mania">Peter Schiff Doesn&#8217;t &#8216;Hate Bitcoin&#8217; But Warns &#8216;Millions&#8217; Will Lose More Than They Can Afford In &#8216;Speculative Mania&#8217;</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$BTC

$DOGE

$SOL

$92,000 Is Bitcoin's Key Support — Here's What Top Analyst Says Will Happen If It Fails

<p>Ratings for Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Eton Pharmaceuticals, revealing an average target of $15.2, a high estimate of $18.00, and a low estimate of $11.00. This upward trend is evident, with the current average reflecting a 22.58% increase from the previous average price target of $12.40.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736359241_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Eton Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chase Knickerbocker</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$17.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Chase Knickerbocker</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Eton Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eton Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Eton Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Eton Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ETON/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Eton Pharmaceuticals analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Eton Pharmaceuticals</h2>
<p>Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.</p>
<h3>Eton Pharmaceuticals: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Eton Pharmaceuticals showcased positive performance, achieving a revenue growth rate of <strong>46.9%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Eton Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>6.07%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.26%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Eton Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.85%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Eton Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of <b>0.27</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ETON

The Analyst Verdict: Eton Pharmaceuticals In The Eyes Of 5 Experts

<p>In the last three months, 10 analysts have published ratings on Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $171.6, a high estimate of $206.00, and a low estimate of $140.00. A decline of 5.32% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736359232_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The perception of Booz Allen Hamilton by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$171.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>David Strauss</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$140.00</td>
<td>-</td>
</tr>
<tr>
<td>Noah Poponak</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$158.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Gavin Parsons</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$159.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$177.00</td>
<td>$206.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$155.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Howard Rubel</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>David Strauss</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$175.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$206.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$185.00</td>
<td>$165.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Booz Allen Hamilton. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Booz Allen Hamilton compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Booz Allen Hamilton's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Booz Allen Hamilton's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BAH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Booz Allen Hamilton analyst ratings.</strong></a></p>
<h2>Discovering Booz Allen Hamilton: A Closer Look</h2>
<p>Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.</p>
<h3>Booz Allen Hamilton: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Booz Allen Hamilton's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>18.01%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Booz Allen Hamilton's net margin excels beyond industry benchmarks, reaching <strong>12.4%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Booz Allen Hamilton's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>34.15%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Booz Allen Hamilton's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>5.77%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Booz Allen Hamilton's debt-to-equity ratio surpasses industry norms, standing at <strong>3.01</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About Booz Allen Hamilton Stock

<p>In the preceding three months, 14 analysts have released ratings for Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $87.71, a high estimate of $98.00, and a low estimate of $80.00. Witnessing a positive shift, the current average has risen by 4.7% from the previous average price target of $83.77.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736359224_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Nasdaq. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$91.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Kevin Heal</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Patrick O'Shaughnessy</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$82.00</td>
<td>-</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$84.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Nasdaq. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Nasdaq compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Nasdaq's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Nasdaq's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NDAQ/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Nasdaq analyst ratings.</strong></a></p>
<h2>Delving into Nasdaq's Background</h2>
<p>Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.</p>
<h3>Nasdaq's Financial Performance</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Nasdaq displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>31.08%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Nasdaq's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>16.09%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Nasdaq's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>2.79%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Nasdaq's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>1.01%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.93</strong>, Nasdaq faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NDAQ

Demystifying Nasdaq: Insights From 14 Analyst Reviews

<p>During the last three months, 5 analysts shared their evaluations of Netstreit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTST#NYSE">NTST</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $18.05, a high estimate of $19.25, and a low estimate of $15.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.39%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736359215_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A clear picture of Netstreit's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haendel St. Juste</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ki Bin Kim</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Simon Yarmak</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$19.25</td>
<td>$19.50</td>
</tr>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$19.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Netstreit. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Netstreit compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Netstreit's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Netstreit's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NTST/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Netstreit analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Netstreit</h2>
<p>Netstreit Corp is structured as an umbrella partnership real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants.</p>
<h3>Understanding the Numbers: Netstreit's Finances</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Netstreit's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>22.59%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Netstreit's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-14.0%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Netstreit's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-0.4%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Netstreit's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-0.25%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Netstreit's debt-to-equity ratio is below the industry average at <strong>0.6</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NTST

Demystifying Netstreit: Insights From 5 Analyst Reviews

<p>According to trading platform Autopilot, Nancy Pelosi's stock tracker took the financial world by storm in 2024, delivering a jaw-dropping 54% gain and outshining nearly every hedge fund. Remarkably, it even beat the Inverse Cramer Stock Tracker, designed to <a href="https://www.benzinga.com/etfs/specialty-etfs/24/01/36793492/exclusive-inverse-cramer-etf-shuts-down-how-the-magnificent-7-stocks-factor-in-and-a-broken-c">do the opposite</a> of Jim Cramer's stock picks, which itself posted an impressive 43% gain in 2024. While the result seems almost mythical, it shows the growing fascination with lawmakers' trading disclosures and the investment strategies built around them.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">BREAKING: Pelosi did it &#x1f451;<br /><br />She officially finishes 2024 up 54% and beat out Inverse Cramer for the top portfolio on Autopilot<br /><br />Never doubt the queen of &#8230; <a href="https://t.co/eT941WTdPs">pic.twitter.com/eT941WTdPs</a></p>
<p>&mdash; Nancy Pelosi Stock Tracker &#x265f; (@PelosiTracker_) <a href="https://twitter.com/PelosiTracker_/status/1874859312616759754?ref_src=twsrc%5Etfw">January 2, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"><strong> </strong><strong>for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</strong></a></strong></li>
<li><strong>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</strong></a></strong></li>
</ul>
<h2 class="wp-block-heading">Why Pelosi's Portfolio Matters</h2>
<p>The former Speaker of the House of Representatives' impressive results are highly controversial and we only know about them because of the information made public through the STOCK Act, passed in 2012. This law requires members of Congress to share details about any <a href="https://www.benzinga.com/money/what-stocks-does-nancy-pelosi-own">stock trades</a> worth over $1,000 within 30 to 45 days. The goal of the law was to stop insider trading and make things more transparent. And while that hasn&#8217;t exactly happened, the disclosures have inspired investors to copy lawmakers' trades.</p>
<p>Platforms like Unusual Whales have popularized the concept and ETFs such as <a href="https://www.benzinga.com/quote/NANC/short-interest">NANC</a> (tracking Democratic lawmakers) and <a href="https://www.benzinga.com/quote/KRUZ">KRUZ</a> (tracking Republicans) were developed to model congressional trading strategies.&nbsp;</p>
<p><strong>See Also: <a href="https://www.benzinga.com/money/qnetic-2"><strong>This 12,000 RPM Spinning Battery With Over $100 Million In LOIs Could Be The Missing Link For Green Energy — Here&#8217;s Why Early Investors Are Flocking To Invest Before Funding Closes</strong></a></strong></p>
<h2 class="wp-block-heading">Hedge Funds Left in the Dust</h2>
<p>While hedge funds often prioritize consistent returns and risk management over sheer market outperformance, their 2024 results pale compared to Pelosi's tracker, as they averaged a 10.7% return, according to PivotalPath. Here are some notable examples:</p>
<ul>
<li><strong>Light Street Capital</strong>: 59.4% (a rare exception that exceeded Pelosi's gains)</li>
<li><strong>Discovery Capital</strong>: 52%</li>
<li><strong>D.E. Shaw – Oculus</strong>: 36.1%</li>
<li><strong>Schonfeld Strategic Partners</strong>: 19.7%</li>
<li><strong>Citadel Wellington</strong>: 15.1%</li>
<li><strong>Millennium Management</strong>: 15%</li>
<li><strong>Marshall Wace Eureka Fund</strong>: 14.3%</li>
</ul>
<p>With their intricate strategies, such as arbitrage and shorting, hedge funds aim to deliver stability rather than massive returns, but Pelosi's tracker showed that bold moves often reap bigger rewards.</p>
<h2 class="wp-block-heading">Lawmaker Trades</h2>
<p>The STOCK Act's public disclosures have created an unexpected byproduct: a booming industry around "political trading." The CEO of Unusual Whales told NPR that interest in lawmakers' trades skyrocketed during the COVID-19 pandemic, with viral social media posts highlighting notable trades. Since then, ETFs and platforms based on these trades have gained traction, allowing investors to replicate congressional strategies.</p>
<p><strong>Trending: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks"><strong>this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</strong></a></strong></p>
<p>While these tools are legal, critics argue that the STOCK Act has failed to stop lawmakers from benefiting from inside information. Instead, it has turned their trades into a <a href="https://www.benzinga.com/markets/24/07/40038521/copying-congress-the-bizarre-world-of-political-stock-picking-funds">guide for others to profit</a>.</p>
<h2 class="wp-block-heading">Calls for Reform Grow Louder</h2>
<p><a href="https://www.benzinga.com/startups/24/11/41850071/someone-asked-nancy-pelosi-the-greatest-options-trader-of-all-time-what-stocks-to-buy-to-her-face-it-went-exactly-as-youd-imagine">Public pressure</a> to reform congressional trading practices has intensified and <a href="https://www.congress.gov/bill/118th-congress/senate-bill/1171">proposals</a> like <a href="https://www.benzinga.com/government/24/07/39940279/senate-committee-approves-congress-stock-trading-ban-whats-next">the ETHICS Act would ban lawmakers</a> and their families from trading individual stocks altogether. However, progress on these reforms has been slow, with some lawmakers saying it might discourage people from entering public service.</p>
<p>Supporters of reforms believe these changes would help people trust Congress more and even small adjustments, like requiring same-day disclosures of trades, could make a big difference in accountability and transparency.</p>
<p>Tools like the Pelosi Tracker shine a spotlight on congressional trading and reveal deeper issues about trust and ethics in public institutions. While products like NANC and KRUZ offer a clever way to profit from lawmakers' trades, they also stress the need for comprehensive reform.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>You can invest today for just $0.26/share with a $1000 minimum.</strong></a></strong></li>
<li><strong>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund"><strong>7-9% target yield with monthly dividends would you invest in it</strong></a></strong><strong>?</strong></li>
</ul>


Nancy Pelosi Outperformed Nearly Every Hedge Fund In 2024 – Even Beating The Infamous Inverse Cramer Stock Tracker

<p>TD Cowen  analyst Robert Moskow   maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Buy and lowers the price target from $110 to $100.</p>


Price Target

TD Cowen Maintains Buy on Colgate-Palmolive, Lowers Price Target to $100

<p>TD Cowen  analyst Vivien Azer   maintains Anheuser-Busch InBev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>) with a Hold and lowers the price target from $65 to $55.</p>


TD Cowen Maintains Hold on Anheuser-Busch InBev, Lowers Price Target to $55

<p>On Tuesday, <strong>Blackstone Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>), through private equity funds managed by the firm, inked a definitive deal to make a significant <a target="_blank" href="https://www.blackstone.com/news/press/citrin-cooperman-a-leading-professional-services-firm-to-receive-significant-investment-as-blackstone-acquires-stake-from-new-mountain-capital/" rel="noreferrer noopener">investment </a>in <strong>Citrin Cooperman Advisors LLC </strong>for an undisclosed amount<strong>.</strong></p>
<p>As part of the deal, Blackstone will acquire its stake in the firm from New Mountain Capital LLC.</p>
<p>Citrin Cooperman, established in 1979, provides tax, advisory, and accounting services to help businesses and individuals. The firm serves over 15,000 clients worldwide, focusing on building lasting relationships.</p>
<p>The deal values Citrin at over $2 billion and is part of a growing trend where private equity firms are acquiring stakes in midsize audit and consulting firms in the U.S., as per <a target="_blank" href="https://www.wsj.com/articles/blackstone-buying-stake-in-accounting-firm-citrin-cooperman-166c66e4?mod=business_feat1_deals_pos3" rel="noreferrer noopener">WSJ</a>.</p>
<p>Alan Badey, CEO of Citrin Cooperman, stated that this investment will help&nbsp;the company expand its services and technology while staying committed to fostering a top-tier firm culture and providing an exceptional client experience.</p>
<p>In November, Blackstone agreed to acquire <strong>Retail Opportunity Investments Corp. </strong>for $17.50 per share in an all-cash deal <a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/41782212/whats-going-on-with-blackstone-stock-today" rel="noreferrer noopener">valued at $4 billion</a>.</p>
<p>The purchase price represented a premium of 34% to Retail Opportunity Investments' closing share price on July 29, 2024, the last trading day before news reports of a potential sale.</p>
<p>Investors can gain exposure to the stock via&nbsp;<strong>AdvisorShares Gerber Kawasaki ETF </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GK#NYSE">GK</a>) and <strong>EA Series Trust WHITEWOLF Publicly Listed Private Equity ETF </strong>(BATS:<a class="ticker" href="https://www.benzinga.com/stock/LBO#BATS">LBO</a>).</p>
<p><strong>Price Action: </strong>BX shares are down 0.04% at $171.28 at the last check Wednesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42822291/2025-industry-shake-up-goldman-highlights-kkr-raymond-james-hamilton-lane" target="_blank" rel="noreferrer noopener">2025 Industry Shake-Up: Goldman Highlights KKR, Raymond James, Hamilton Lane</a></strong></li>
</ul>
<p><em>Image via Shutterstock.</em></p>


Equities

Large Cap

Blackstone Invests Big In Citrin Cooperman: Private Equity Fuels Growth In Tax and Advisory

CPRX

Trading Halt: Halt status updated at 12:55:00 PM ET: Quotation Resumption: News and Resumption Times

<p>Over the next few days the CES 2025 tech show will be happening, with traders watching NVDA's events and presentations especially closely. It's without a doubt going to have a major impact upon NVDA's stock performance for weeks to come.</p>
<p>It's hard not to marvel at the potential for UBER and NVDA to partner in the automotive space, and not to think "bullish" when you see all the new technologies being revealed.</p>
<p>But my PFP (positioning, flows and price action) system tells a tale that can't be ignored. Let's dive into it.</p>
<h2 class="wp-block-heading">Options Positioning in $NVDA</h2>
<p>Heading into the event on Tuesday, we had the 140 TGS (top gamma strike) which is our first layer of support, with 145 and 150 standing out as major resistance levels, and a lot less fuel above 150.</p>
<p>I commented on the push above 150 yesterday during our live Benzinga Option School that I didn't think it would hold above 150 for long. This is simply because a) there was little positional fuel above 150, b) traders were selling calls hand over fist above 150 (up to 160) and c) only shares were buying heavily yesterday above 150.</p>
<p>What this translates to me is it will be hard for NVDA to retain gains above 150 or past 160 short term (without a major CES bullish catalyst). For it to be comfortable (as of this writing around 1:10PM Eastern on Tuesday) near the 140 TGS is not surprising. But what happens if it loses 140 today or in overnight action?</p>
<p>Simply put, below 140, puts are in control and that puts 135 and 130 into focus. Below that there is very little fuel for continued downside.</p>
<p>Thus, option positioning in NVDA is forecasting a high (post-CES) of 160 and a low of 130 with a solid chance of aggregating around the TGS at 140.</p>
<h2 class="wp-block-heading">Price Action in $NVDA</h2>
<p>Looking at the 5-minute chart below in NVDA over the last few sessions, we've seen solid gains on Friday and Monday ahead of CES, but impulsive selling today for most of the session with only a corrective bounce once the European session closed.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08124356/NVDA_2025-01-07_11-15-44-1024x502.png" alt="" class="wp-image-724607" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08124356/NVDA_2025-01-07_11-15-44-1024x502.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08124356/NVDA_2025-01-07_11-15-44-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08124356/NVDA_2025-01-07_11-15-44-768x377.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08124356/NVDA_2025-01-07_11-15-44-1536x753.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08124356/NVDA_2025-01-07_11-15-44.png 1835w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p>The impulsive selling to start the session and corrective bounce suggests that from a price action perspective, there is likely more downside action unless we get a bullish catalyst from CES soon. We could see it bouncing to the session VWAP around 145, but any corrective bounces should be met with more selling.</p>
<p>What this is translating to is a less than enthusiastic short-term reaction from CES thus far.</p>
<h2 class="wp-block-heading">Flows in $NVDA</h2>
<p>This is the most interesting, and in my opinion, contradictory part of NVDA's story today. I'd also like to note it was the opposite in terms of flows yesterday, so I've been witnessing a different story the last two days from the options market and shares market.</p>
<p>On Tuesday, shortly before the European close (11am Eastern), I noticed a strong surge in call buying/positive deltas while puts remained consistently long puts. Normally positive deltas suggest call buying and thus should lift the stock. This is why we have to tie in the story for Monday as well.</p>
<p>For Monday, I saw call selling (bearish) along with an almost similar amount of put buying (bearish).</p>
<p>What we take from this is the call buying/positive deltas on the day are the short calls being closed today (thus via long calls) as the juice/credit had been pulled out from today's selloff.</p>
<p>What is also interesting is that despite the bearish option flows on Monday, the stock gained until the last two hours of trading. This suggests the gains were due to share buying, not options. Today (Tuesday), traders are not piling on massive bearish bets, so today, I think shares are being dumped en masse, thus the options flow has been discordant with the share flow over the last two sessions.</p>
<h2 class="wp-block-heading">How We're Trading $NVDA</h2>
<p>I'd like to see how the market closes on the day before making a trade on NVDA. If we can recover 145, then there is some hope for a push back into 150 by tomorrow. But if we get another impulsive leg down, then I think 140 is on deck.<br /><br />What I'd really like to see is how the positioning changes after Tuesday, which will be accounted for in our data models between 12-3am Eastern. Hence, on Wednesday morning, we'll see which strikes gained/lost as a result of CES on Tuesday, and thus where bulls and bears think NVDA is going next.</p>
<p>Overall, the response has been underwhelming from a PFP perspective, thus we're looking to sell rallies with corrective moves into resistance targeting 140. But we're open to 140 providing a strong bounce should it hold today and share buyers step in.</p>
<p>Because of the high IV premium from the event, we suggest not trading single legs as the IV drain will be significant. We recommend trading spreads to reduce IV risk or potentially BWB's (broken wing butterflies) which both reduces IV risk, but also takes advantage of it.</p>
<p>I'll share our live trade ideas in real time with our members of the <a href="https://www.benzinga.com/premium/ideas/benzinga-options-school-webinar">Benzinga Option School</a> or <a href="https://www.benzinga.com/premium/ideas/trading-waves-997-offer/">Trading Waves</a>. We hope to see you there.</p>
<p>Image via Shutterstock</p>


Opinion

How to Trade NVDA This Week

<p>The U.S. reported its <a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">first human death</a> from the H5 bird flu strain this week, causing a spike in vaccine developer stocks <strong>Moderna </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), <strong>Novavax </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), <strong>CureVac </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) and <strong>Pfizer </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).</p>
<p>Vaccine production efforts are ramping up as health officials monitor the outbreak closely. In<a href="https://www.cdc.gov/bird-flu/situation-summary/index.html" target="_blank" rel="noreferrer noopener"> an update </a>on Monday, CDC said there have been 66 confirmed cases in the U.S. in the 2024 outbreak. </p>
<p>CDC said the public risk remains low. Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/news/25/01/42851023/why-novavax-nvax-stock-is-rising">Why Novavax (NVAX) Stock Is Rising</a></strong></p>
<h3 class="wp-block-heading"><strong>Vaccine Providers in the Limelight</strong></h3>
<p>In the U.S., vaccines against H5N1 are already stockpiled. Approved shots include those from <strong>Sanofi</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), <strong>CSL Seqirus</strong>, and <strong>ID Biomedical Corporation of Quebec</strong>, a subsidiary of <strong>GlaxoSmithKline</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), which collectively secured $72 million in funding from the U.S. health department in October to boost the production of bird flu vaccines. These traditional vaccines, developed years ago, target older H5N1 strains but are expected to offer some protection.</p>
<p>Moderna, backed by $176 million from the U.S. government's BARDA, is working on an updated mRNA H5N1 vaccine. Other players, including Pfizer and GSK (in collaboration with CureVac), are testing similar candidates.</p>
<h3 class="wp-block-heading"><strong>ETFs in Focus</strong></h3>
<p>For investors who want to play the trend but are wary of choosing individual biotech stocks, here are three ETFs that offer diversified exposure to the biotech companies leading the vaccine efforts. With a mix of traditional and mRNA vaccine developers in focus, these funds could benefit as the world prepares for a potential bird flu pandemic.</p>
<p><strong>iShares Genomics Immunology and Healthcare ETF </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDNA#NYSE">IDNA</a>) tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index, and has already gained 2.5% so far this year. The fund has an expense ratio of 0.47%, and $129.97 million in assets under management (AUM). The fund has currently invested 4.48% of its assets in Moderna. Sanofi, GSK and Novavax are also part of its portfolio of 51 equity holdings.</p>
<p><strong>First Trust Nasdaq Pharmaceuticals ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>) derives its investment strategy from the Nasdaq US Benchmark Index, and has an expense ratio of 0.60%. Pfizer is one of its top holdings, with 7.28% of assets allocated to it.</p>
<p><strong>SPDR S&amp;P Biotech ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>) mirrors the S&amp;P&nbsp;Biotechnology Select Industry&nbsp;Index, and charges a 0.35% expense ratio. Out of its present AUM of $6.37 billion, Moderna holds 2.58%. Almost 100% of its holdings are exposed to the biotechnology sector, with only about 0.04% invested in the pharmaceutical sector.</p>
<h3 class="wp-block-heading"><strong>The Bird Flu Menace </strong></h3>
<p>The bird flu scare in humans ratcheted higher in late 2024 when a 13-year-old girl in Canada fell critically ill with H5N1 and required a ventilator. Around the same time, the U.S. reported its first severe case in an elderly patient in Louisiana.</p>
<p>Health experts warn that vigilance is key to preventing mutations that could trigger a pandemic. While the technology to develop vaccines quickly is available, governments may need to fund large-scale clinical trials in advance to ensure rapid distribution in case of a health emergency.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/25/01/42878295/quantum-stocks-tumble-why-rigetti-ionq-and-d-wave-are-falling"><strong>Quantum Stocks Tumble: Why Rigetti, IonQ and D-Wave Are Falling</strong></a></li>
</ul>
<p><em>Photo: Shutterstock.</em></p>


Biotech

Sector ETFs

Health Care

ETFs

CVAC

FTXH

IDNA

MRNA

NVAX

Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies

<p>TD Cowen  analyst Robert Moskow   maintains BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) with a Buy and raises the price target from $83 to $86.</p>


BRBR

TD Cowen Maintains Buy on BellRing Brands, Raises Price Target to $86

<p>Craig-Hallum  analyst Chase Knickerbocker   maintains Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) with a Buy and raises the price target from $15 to $18.</p>


Craig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $18

What Moved Markets This Week

Blue Bird Is Positioned For Continued Growth, Looks Even More Attractive Now

EV Company News For The Month Of November 2024

Blue Bird: Oversold And Undervalued Heading Into 2025

Analyst Chris Pierce of Needham reiterated a Buy rating on Blue Bird (BLBD – Research Report), retaining the price target of $66.00. Chris Pierce h...

Positive Outlook on Blue Bird: Strategic Focus on Electric and Propane Bus Markets Drives Growth Potential

In a report released yesterday, Michael Shlisky from D.A. Davidson maintained a Buy rating on Blue Bird (BLBD – Research Report), with a price targ...

D.A. Davidson Remains a Buy on Blue Bird (BLBD)

Blue Bird's Unloved Status Triggers Rich Capital Appreciation Prospects

16:18 EST Blue Bird (BLBD) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving brea...

Blue Bird files automatic mixed securities shelf

Craig-Hallum analyst Eric Stine maintained a Buy rating on Blue Bird (BLBD – Research Report) today. The company's shares closed last Friday at $41...

Craig-Hallum Reaffirms Their Buy Rating on Blue Bird (BLBD)

EV Company News For The Month Of December 2024

ADSK

AYRO

BAMXF

BATT

BBCP

BCCMY

BLBD

BLNK

BMCLF

BYDDF

BYDDY

BYMOF

CPRT

DELL

DNFGF

DNFGY

ENPH

EVGO

EVGOW

EVTV

FUJHF

FUJHY

GELYF

GELYY

GOEV

GOEVW

GWLLF

GWLLY

HNDAF

HYLN

HYMTF

INTU

KNDI

LAAOF

LCID

MAHMF

MBGAF

MBGYY

MMTOF

MSTR

MZDAF

MZDAY

NIOIF

NSANF

NSANY

NVDA

POAHF

POAHY

PSNY

PSNYW

RACE

RIVN

RNLSY

RNSDF

SCHD

SMCI

STLA

SZKMF

SZKMY

TOYOF

TSLA

ULTA

VFSWW

VLKAF

VLKPF

VWAGY

VWAPY

WKHS

XIACF

XIACY

XPEV

XPNGF

Press Releases

Blue Bird Announces Resignation of President; Phil Horlock to Remain as President and CEO

Amentum Announces Board of Directors Effective Post Merger with Jacobs Businesses

Blue Bird Applauds EPA's $965 Million Clean School Bus Funding to Accelerate Adoption of Zero-Emission Student Transportation

Blue Bird Delivers First Fleet of Propane-Powered Buses to School District of Philadelphia

Blue Bird Announces FY2024 Preliminary Unit Sales and Revenue

Blue Bird Appoints Edward Hightower to its Board of Directors

Blue Bird to Report Fiscal 2024 Fourth Quarter and Full Year Results on November 25, 2024

Blue Bird Reports Record Fiscal 2024 Results, Beating Guidance; Raises Fiscal 2025 Guidance and Long-Term Outlook

Blue Bird Joint Venture Micro Bird to Establish Bus Manufacturing Facility in New York State

Wilkes County Schools Leads the Way as Georgia's First District with an All-Clean School Bus Fleet

Comments

Blue Bird

Intérêt court

Blue Bird (NASDAQ:BLBD) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL